CHILDREN'S CANCER GROUP

费城儿童医院为儿童的科学研究做出了贡献。 在过去的25年里，儿童癌症小组在病人方面， 进入研究，在委员会和战略小组的科学领导， 以及试点研究的启动和实施。 具体 贡献如下：1）使用骨髓移植 在神经母细胞瘤的高剂量强化治疗之后; 2） 神经肿瘤学的临床和生物学研究， 随机分组试验; 3）开始一种方法， 使用随机数字拨号技术的流行病学研究， 视网膜母细胞瘤、脑肿瘤与父母职业的群体研究 通过资助赠款; 4）提供领导和专业知识， 癌症治疗的晚期效应研究;以及5）进行以下研究： 白血病、霍奇金病、淋巴瘤、横纹肌肉瘤和脑肿瘤 作为集团的早期试点。 参与的研究人员 这一奋进将继续为患者提供高质量的数据， 进入研究以及在基础科学领域的领导，晚 治疗效果，神经肿瘤学，骨髓移植，生物 反应调节剂和病因学及预防。 100多名患者 每年从CHOP及其附属机构进入CCG研究- 威尔明顿医疗中心、盖辛格医疗中心和阿尔伯特 爱因斯坦医院，超过1,000人正在接受研究;这是 预计这一数字将在未来增加，因为研究 现在还没有的疾病已经开始。 CHOP研究人员现在主持 主要策略组（ANL、淋巴瘤和软组织肉瘤）， 在所有研究领域提供委员会领导。 有23 该机构的研究者拥有108个研究职位 委员会、战略小组或科学委员会，其中20个在 领导地位。 我们将继续招募所有符合条件的患者 并符合研究参与方面的组要求， 除了在上述具体领域发挥领导作用外。

The Children's Hospital of Philadelphia has contributed to the science of the Childrens Cancer Group in the last 25 years with regard to patient entry on study, scientific leadership in committees and strategy groups, and the initiation and performance of pilot studies. Specific contributions have been the following: 1) Use of bone marrow transplant following high dose intensive therapy for neuroblastoma; 2) Development of clinical and biology studies in neuro-oncology that will be incorporated into randomized Group trials; 3) Initiation of a method of performing epidemiologic studies utilizing the random-digit dialing technique in Group studies of retinoblastoma, brain tumors and parental occupation through funded grants; 4) Providing leadership and expertise in developing studies of late effects of cancer therapy; and 5) Performing studies for leukemia, Hodgkin's disease, lymphomas, rhabdomyosarcoma, and brain tumors serving as early pilots for the Group. The investigators participating in this endeavor will continue to provide data of high quality for patients entered on study as well as leadership in the areas of basic science, late effects of therapy, neuro-oncology, bone marrow transplantation, biologic response modifiers and etiology and prevention. More than 100 patients have been entered on CCG studies annually from CHOP and its affiliates -- the Wilmington Medical Center, Geisinger Medical Center and Albert Einstein Hospital, and more than 1,000 are being followed on study; it is expected that this number will increase in the future as studies for diseases not now available are initiated. CHOP investigators now chair major Strategy Groups (ANL, Lymphoma and Soft Tissue Sarcoma) and are providing committee leadership in all areas of study. There are 23 investigators in this institution holding 108 positions on study committees, strategy groups, or scientific committees, 20 of them being in positions of leadership. We will continue to enroll all eligible patients and to conform to group requirements with regard to study participation, in addition to providing leadership in the specific areas noted above.